Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8204-8223

  Yu, Li Fang ^a,d   Zhang, Han Kun ^a,d   Caldarone, Barbara J ^b   Eaton, J Brek ^c   Lukas, Ronald J ^c   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLOROPYRIDIN 3 YL) 1,4 DIAZEPANE; 1 ETHYL 11A,12 DIHYDROXY 6,8,10,13 TETRAMETHOXYDODECAHYDRO 2H 3,6A,12 (EPIETHANE[1,1,2]TRIYL) 7,9 METHANONAPHTHO[2,3 B]AZOCIN 3(4H) YL METHYL 2 (3 METHYL 2,5 DIOXOPYRROLIDIN 1 YL)BENZOATE; 1,2,3,4,5,6 HEXAHYDRO 8H 1,5 METHANOPYRIDO[1,2 A][1,5]DIAZOCIN 8 ONE; 11 BROMO 1,2,3,4,5,6 HEXAHYDRO 8H 1,5 METHANOPYRIDO[1,2 A][1,5]DIAZOCIN 8 ONE; 2 (TERT BUTYLAMINO) 1 (3 CHLOROPHENYL)PROPAN 1 ONE; 2 METHOXY 2,3,5,6,8,9,10,13 OCTAHYDRO 1H,12H PYRANO[4',3':3,4]PYRIDO[2,1 I]INDOL 12 ONE; 2 [2 [5 [(AZETIDIN 2 YL)METHOXY]PYRIDIN 3 YL]CYCLOPROPYL]ETHAN 1 OL; 2 [5 [5 (AZETIDIN 2 YLMETHOXY)PYRIDIN 3 YL]ISOXAZOL 3 YL]ETHAN 1 OL; 3 (AZETIDIN 2 YLMETHOXY) 5 IODOPYRIDINE; 3 (AZETIDIN 2 YLMETHOXY)PYRIDINE; 3 ETHYNYL 5 (1 METHYLPYRROLIDIN 2 YL)PYRIDINE; 4 CHLORO N (QUINUCLIDIN 3 YL)BENZAMIDE; 5 (5 ISOPROPOXYPYRIDIN 3 YL) N METHYLPENT 4 EN 2 AMINE; 5 (AZETIDIN 2 YLMETHOXY) 3 METHYLISOXAZOLE; 6 [5 (AZETIDIN 2 YLMETHOXY)PYRIDIN 3 YL]HEX 5 YN 1 OL; 7 (PYRIDIN 3 YL) 1,7 DIAZASPIRO[4.4]NONANE; 7 (TRIFLUOROMETHYL) 2,3,4,5 TETRAHYDRO 1H 1,5 METHANOBENZO[D]AZEPINE; 9 (PYRIDIN 2 YL) 1,2,3,4,5,6 HEXAHYDRO 8H 1,5 METHANOPYRIDO[1,2 A][1,5]DIAZOCIN 8 ONE; ANTIDEPRESSANT AGENT; CYTISINE; MECAMYLAMINE; MUSCARINIC RECEPTOR; N PHENYL 5 (PYRROLIDIN 2 YLMETHOXY)PYRIDIN 3 AMINE; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VARENICLINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; ALKALOID; AZETIDINE DERIVATIVE; AZOCINE DERIVATIVE; LIGAND; NICOTINIC RECEPTOR; QUINOLIZINE DERIVATIVE;

AMINO ACID SEQUENCE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DEPRESSION; DRUG POTENCY; HUMAN; NONHUMAN; PROTEIN TARGETING; CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ALKALOIDS; ANTIDEPRESSIVE AGENTS; AZETIDINES; AZOCINES; DEPRESSION; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; QUINOLIZINES; RECEPTORS, NICOTINIC;

EID: 84908377325     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401937a     Document Type: Article

References (154)

1. World Health Organization. Mental health and development: targeting people with mental health conditions as a vulnerable group; WHO Press: Geneva, Switzerland, 2010.
2. Berton, O.; Nestler, E. J. New approaches to antidepressant drug discovery: beyond monoamines Nat. Rev. Neurosci. 2006, 7, 137-151
3. Ruhe, H. G.; Huyser, J.; Swinkels, J. A.; Schene, A. H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review J. Clin. Psychiatry 2006, 67, 1836-1855
4. Sinyor, M.; Schaffer, A.; Levitt, A. The sequenced treatment alternatives to relieve depression (STARD) trial: a review Can. J. Psychiatry 2010, 55, 126-135
5. Janowsky, D. S.; el-Yousef, M. K.; Davis, J. M.; Sekerke, H. J. A cholinergic-adrenergic hypothesis of mania and depression Lancet. 1972, 2, 632-635
6. Overstreet, D. H. Selective breeding for increased cholinergic function: development of a new animal model of depression Biol. Psychiatry 1986, 21, 49-58
7. Pucilowski, O.; Overstreet, D. H.; Rezvani, A. H.; Janowsky, D. S. Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression Physiol. Behav. 1993, 54, 1215-1220
8. Mineur, Y. S.; Obayemi, A.; Wigestrand, M. B.; Fote, G. M.; Calarco, C. A.; Li, A. M.; Picciotto, M. R. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 3573-3578
9. Philip, N. S.; Carpenter, L. L.; Tyrka, A. R.; Price, L. H. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature Psychopharmacology 2010, 212, 1-12
10. George, T. P.; Sacco, K. A.; Vessicchio, J. C.; Weinberger, A. H.; Shytle, R. D. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study J. Clin. Psychopharmacol. 2008, 28, 340-344
11. Shytle, R. D.; Silver, A. A.; Lukas, R. J.; Newman, M. B.; Sheehan, D. V.; Sanberg, P. R. Nicotinic acetylcholine receptors as targets for antidepressants Mol. Psychiatry 2002, 7, 525-535
12. Philip, N. S.; Carpenter, L. L.; Tyrka, A. R.; Whiteley, L. B.; Price, L. H. Varenicline augmentation in depressed smokers: an 8-week, open-label study J. Clin. Psychiatry 2009, 70, 1026-1031
13. Furey, M. L.; Drevets, W. C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial Arch. Gen. Psychiatry 2006, 63, 1121-1129
14. Drevets, W. C.; Furey, M. L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial Biol. Psychiatry 2010, 67, 432-438
15. Charles, H. C.; Lazeyras, F.; Krishnan, K. R.; Boyko, O. B.; Payne, M.; Moore, D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy Prog. Neuropsychopharmacol. Biol. Psychiatry 1994, 18, 1121-1127
16. Steingard, R. J.; Yurgelun-Todd, D. A.; Hennen, J.; Moore, J. C.; Moore, C. M.; Vakili, K.; Young, A. D.; Katic, A.; Beardslee, W. R.; Renshaw, P. F. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy Biol. Psychiatry 2000, 48, 1053-1061
17. Arias, H. R.; Rosenberg, A.; Targowska-Duda, K. M.; Feuerbach, D.; Jozwiak, K.; Moaddel, R.; Wainer, I. W. Tricyclic antidepressants and mecamylamine bind to different sites in the human alpha4beta2 nicotinic receptor ion channel Int. J. Biochem. Cell Biol. 2010, 42, 1007-1018
18. Hennings, E. C.; Kiss, J. P.; Vizi, E. S. Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices Brain Res. 1997, 759, 292-294
19. Fryer, J. D.; Lukas, R. J. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function J. Neurochem. 1999, 72, 1117-1124
20. Lopez-Valdes, H. E.; Garcia-Colunga, J. Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake Mol. Psychiatry 2001, 6, 511-519
21. Weber, M. L.; Hofland, C. M.; Shaffer, C. L.; Flik, G.; Cremers, T.; Hurst, R. S.; Rollema, H. Therapeutic doses of antidepressants are projected not to inhibit human alpha4beta2 nicotinic acetylcholine receptors Neuropharmacology 2013, 72, 88-95
22. Popik, P.; Kozela, E.; Krawczyk, M. Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram Br. J. Pharmacol. 2003, 139, 1196-1202
23. Andreasen, J. T.; Nielsen, E. O.; Christensen, J. K.; Olsen, G. M.; Peters, D.; Mirza, N. R.; Redrobe, J. P. Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test J. Psychopharmacol. 2011, 25, 1347-1356
24. Eglen, R. M. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function Auton. Autacoid Pharmacol. 2006, 26, 219-233
25. Mineur, Y. S.; Picciotto, M. R. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis Trends Pharmacol. Sci. 2010, 31, 580-586
26. Lukas, R. J.; Changeux, J. P.; Le Novere, N.; Albuquerque, E. X.; Balfour, D. J.; Berg, D. K.; Bertrand, D.; Chiappinelli, V. A.; Clarke, P. B.; Collins, A. C.; Dani, J. A.; Grady, S. R.; Kellar, K. J.; Lindstrom, J. M.; Marks, M. J.; Quik, M.; Taylor, P. W.; Wonnacott, S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits Pharmacol. Rev. 1999, 51, 397-401
27. Changeux, J. P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice Nat. Rev. Neurosci. 2010, 11, 389-401
28. Arneric, S. P.; Holladay, M.; Williams, M. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research Biochem. Pharmacol. 2007, 74, 1092-1101
29. Picciotto, M. R.; Zoli, M.; Rimondini, R.; Lena, C.; Marubio, L. M.; Pich, E. M.; Fuxe, K.; Changeux, J. P. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine Nature 1998, 391, 173-177
30. Ma, Z.; Strecker, R. E.; McKenna, J. T.; Thakkar, M. M.; McCarley, R. W.; Tao, R. Effects on serotonin of (-)nicotine and dimethylphenylpiperazinium in the dorsal raphe and nucleus accumbens of freely behaving rats Neuroscience 2005, 135, 949-958
31. Tucci, S. A.; Genn, R. F.; File, S. E. Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: possible role of alpha7 receptors Neuropharmacology 2003, 44, 367-373
32. Dominguez del Toro, E.; Juiz, J. M.; Peng, X.; Lindstrom, J.; Criado, M. Immunocytochemical localization of the alpha 7 subunit of the nicotinic acetylcholine receptor in the rat central nervous system J. Comp. Neurol. 1994, 349, 325-342
33. Seguela, P.; Wadiche, J.; Dineley-Miller, K.; Dani, J. A.; Patrick, J. W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium J. Neurosci. 1993, 13, 596-604
34. Albuquerque, E. X.; Pereira, E. F.; Alkondon, M.; Rogers, S. W. Mammalian nicotinic acetylcholine receptors: from structure to function Physiol. Rev. 2009, 89, 73-120
35. Gotti, C.; Riganti, L.; Vailati, S.; Clementi, F. Brain neuronal nicotinic receptors as new targets for drug discovery Curr. Pharm. Des. 2006, 12, 407-428
36. Caldarone, B. J.; Harrist, A.; Cleary, M. A.; Beech, R. D.; King, S. L.; Picciotto, M. R. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation Biol. Psychiatry 2004, 56, 657-664
37. Rabenstein, R. L.; Caldarone, B. J.; Picciotto, M. R. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice Psychopharmacology 2006, 189, 395-401
38. Caldarone, B. J.; Wang, D.; Paterson, N. E.; Manzano, M.; Fedolak, A.; Cavino, K.; Kwan, M.; Hanania, T.; Chellappan, S. K.; Kozikowski, A. P.; Olivier, B.; Picciotto, M. R.; Ghavami, A. Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380 Psychopharmacology 2011, 217, 199-210
39. Saricicek, A.; Esterlis, I.; Maloney, K. H.; Mineur, Y. S.; Ruf, B. M.; Muralidharan, A.; Chen, J. I.; Cosgrove, K. P.; Kerestes, R.; Ghose, S.; Tamminga, C. A.; Pittman, B.; Bois, F.; Tamagnan, G.; Seibyl, J.; Picciotto, M. R.; Staley, J. K.; Bhagwagar, Z. Persistent beta2-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder Am. J. Psychiatry 2012, 169, 851-859
40. Meyer, P. M.; Strecker, K.; Kendziorra, K.; Becker, G.; Hesse, S.; Woelpl, D.; Hensel, A.; Patt, M.; Sorger, D.; Wegner, F.; Lobsien, D.; Barthel, H.; Brust, P.; Gertz, H. J.; Sabri, O.; Schwarz, J. Reduced alpha4beta2-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease Arch. Gen. Psychiatry 2009, 66, 866-877
41. Arias, H. R.; Fedorov, N. B.; Benson, L. C.; Lippiello, P. M.; Gatto, G. J.; Feuerbach, D.; Ortells, M. O. Functional and structural interaction of (-)-reboxetine with the human alpha4beta2 nicotinic acetylcholine receptor J. Pharmacol. Exp. Ther. 2013, 344, 113-123
42. Klink, R.; de Kerchove d'Exaerde, A.; Zoli, M.; Changeux, J. P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei J. Neurosci. 2001, 21, 1452-1463
43. Wu, J.; Lukas, R. J. Naturally-expressed nicotinic acetylcholine receptor subtypes Biochem. Pharmacol. 2011, 82, 800-807
44. Quik, M.; Perez, X. A.; Grady, S. R. Role of alpha6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders Biochem. Pharmacol. 2011, 82, 873-882
45. Gotti, C.; Zoli, M.; Clementi, F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance Trends Pharmacol. Sci. 2006, 27, 482-491
46. Perry, D. C.; Xiao, Y.; Nguyen, H. N.; Musachio, J. L.; Davila-Garcia, M. I.; Kellar, K. J. Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography J. Neurochem. 2002, 82, 468-481
47. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors Biochem. Pharmacol. 2009, 78, 703-711
48. de Filippi, G.; Mogg, A. J.; Phillips, K. G.; Zwart, R.; Sher, E.; Chen, Y. The subtype-selective nicotinic acetylcholine receptor positive allosteric potentiator 2087101 differentially facilitates neurotransmission in the brain Eur. J. Pharmacol. 2010, 643, 218-224
49. Gong, C. L.; Chiu, Y. T.; Lin, N. N.; Cheng, C. C.; Lin, S. Z.; Lee, T. J.; Kuo, J. S. Regulation of the common carotid arterial blood flow by nicotinic receptors in the medulla of cats Br. J. Pharmacol. 2006, 149, 206-214
50. Shytle, R. D.; Silver, A. A.; Sheehan, K. H.; Sheehan, D. V.; Sanberg, P. R. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine Depression Anxiety 2002, 16, 89-92
51. Papke, R. L.; Sanberg, P. R.; Shytle, R. D. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes J. Pharmacol. Exp. Ther. 2001, 297, 646-656
52. George, A. A.; Lucero, L. M.; Damaj, M. I.; Lukas, R. J.; Chen, X.; Whiteaker, P. Function of human alpha3beta4alpha5 nicotinic acetylcholine receptors is reduced by the alpha5(D398N) variant J. Biol. Chem. 2012, 287, 25151-25162
53. Dash, B.; Chang, Y.; Lukas, R. J. Reporter mutation studies show that nicotinic acetylcholine receptor (nAChR) alpha5 subunits and/or variants modulate function of alpha6-nAChR J. Biol. Chem. 2011, 286, 37905-37918
54. Zhong, W.; Gallivan, J. P.; Zhang, Y.; Li, L.; Lester, H. A.; Dougherty, D. A. From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12088-12093
55. Dougherty, D. A.; Stauffer, D. A. Acetylcholine binding by a synthetic receptor: implications for biological recognition Science 1990, 250, 1558-1560
56. Xiu, X.; Puskar, N. L.; Shanata, J. A.; Lester, H. A.; Dougherty, D. A. Nicotine binding to brain receptors requires a strong cation-pi interaction Nature 2009, 458, 534-537
57. Blum, A. P.; Lester, H. A.; Dougherty, D. A. Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 13206-13211
58. Blum, A. P.; Van Arnam, E. B.; German, L. A.; Lester, H. A.; Dougherty, D. A. Binding interactions with the complementary subunit of nicotinic receptors J. Biol. Chem. 2013, 288, 6991-6997
59. Rohde, L. A.; Ahring, P. K.; Jensen, M. L.; Nielsen, E. O.; Peters, D.; Helgstrand, C.; Krintel, C.; Harpsoe, K.; Gajhede, M.; Kastrup, J. S.; Balle, T. Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine alpha4beta2 receptors: unique role of halogen bonding revealed J. Biol. Chem. 2012, 287, 4248-4259
60. Harpsoe, K.; Hald, H.; Timmermann, D. B.; Jensen, M. L.; Dyhring, T.; Nielsen, E. O.; Peters, D.; Balle, T.; Gajhede, M.; Kastrup, J. S.; Ahring, P. K. Molecular determinants of subtype-selective efficacies of cytisine and the novel compound NS3861 at heteromeric nicotinic acetylcholine receptors J. Biol. Chem. 2013, 288, 2559-2570
61. McCormack, T.; Petrovich, R. M.; Mercier, K. A.; DeRose, E. F.; Cuneo, M. J.; Williams, J.; Johnson, K. L.; Lamb, P. W.; London, R. E.; Yakel, J. L. Identification and functional characterization of a novel acetylcholine-binding protein from the marine annelid Capitella teleta Biochemistry 2010, 49, 2279-2287
62. Billen, B.; Spurny, R.; Brams, M.; van Elk, R.; Valera-Kummer, S.; Yakel, J. L.; Voets, T.; Bertrand, D.; Smit, A. B.; Ulens, C. Molecular actions of smoking cessation drugs at alpha4beta2 nicotinic receptors defined in crystal structures of a homologous binding protein Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 9173-9178
63. Zhang, H. K.; Eaton, J. B.; Yu, L. F.; Nys, M.; Mazzolari, A.; van Elk, R.; Smit, A. B.; Alexandrov, V.; Hanania, T.; Sabath, E.; Fedolak, A.; Brunner, D.; Lukas, R. J.; Vistoli, G.; Ulens, C.; Kozikowski, A. P. Insights into the structural determinants required for high-affinity binding of chiral cyclopropane-containing ligands to alpha4beta2-nicotinic acetylcholine receptors: an integrated approach to behaviorally active nicotinic ligands J. Med. Chem. 2012, 55, 8028-8037
64. Cryan, J. F.; Mombereau, C.; Vassout, A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice Neurosci. Biobehav. Rev. 2005, 29, 571-625
65. Dulawa, S. C.; Hen, R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test Neurosci. Biobehav. Rev. 2005, 29, 771-783
66. Fedorov, N. B.; Benson, L. C.; Graef, J.; Lippiello, P. M.; Bencherif, M. Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition J. Pharmacol. Exp. Ther. 2009, 328, 525-532
67. Lippiello, P. M.; Beaver, J. S.; Gatto, G. J.; James, J. W.; Jordan, K. G.; Traina, V. M.; Xie, J.; Bencherif, M. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity CNS Neurosci. Ther. 2008, 14, 266-277
68. Targacept's TC-5214 achieves all primary and secondary outcome measures in Phase 2b trial as augmentation treatment for major depressive disorder. Targacept, Inc., July 15, 2009; http://www.targacept.com/newsroom.
69. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder (MDD). ClinicalTrials.gov, December 29, 2011; http://clinicaltrials.gov/ct2/show/NCT01157078?term=TC5214&rank=17.
70. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. ClinicalTrials.gov, November 19, 2012; http://www.clinicaltrials.gov/ct2/show/NCT01153347.
71. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. ClinicalTrials.gov, November 19, 2012; http://clinicaltrials.gov/ct2/show/results/NCT01180400.
72. Vieta, E.; Thase, M. E.; Naber, D.; D'Souza, B.; Rancans, E.; Lepola, U.; Olausson, B.; Szamosi, J.; Wilson, E.; Hosford, D.; Dunbar, G.; Tummala, R.; Eriksson, H. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant Eur. Neuropsychopharmacol. 2014, 24, 564-574
73. Nickell, J. R.; Grinevich, V. P.; Siripurapu, K. B.; Smith, A. M.; Dwoskin, L. P. Potential therapeutic uses of mecamylamine and its stereoisomers Pharmacol., Biochem. Behav. 2013, 108, 28-43
74. Papke, R. L.; Picciotto, M. R. Nicotine dependence and depression, what is the future for therapeutics? J. Addict. Res. Ther. 2012, 3, e105
75. Fedorov, N.; Moore, L.; Gatto, G.; Jordan, K.; Bencherif, M. Differential effects of TC-5214 [S-(+)-mecamylamine] and TC-5213 [R-(-)-mecamylamine] at low and high sensitivity human alpha4beta2 nicotinic receptors and in animal models of depression and anxiety, 37th Annual Meeting of the Society for Neuroscience, San Diego, CA, Nov 3-7, 2007.
76. Papke, R. L.; Stokes, C.; Muldoon, P.; Imad Damaj, M. Similar activity of mecamylamine stereoisomers in vitro and in vivo Eur. J. Pharmacol. 2013, 720, 264-275
77. Philip, N. S.; Carpenter, L. L.; Tyrka, A. R.; Price, L. H. The nicotinic acetylcholine receptor as a target for antidepressant drug development Sci. World J. 2012, 2012, 104105
78. Mineur, Y. S.; Einstein, E. B.; Seymour, P. A.; Coe, J. W.; O'Neill, B. T.; Rollema, H.; Picciotto, M. R. alpha4beta2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties Behav. Pharmacol. 2011, 22, 291-299
79. Fava, M.; Ramey, T.; Bell, J.; Li, X.; Boyer, S.; Davidson, W.; Billing, B.; Arroyo, S. Augmenting SSRIs with an alpha4beta2 nAChR partial agonist: lack of efficacy in insufficient response major depressive disorder, ISCTM 8th Annual Scientific Meeting, Washington, DC, Feb 21-23, 2012.
80. Ramey, T.; Bell, J.; Boyer, S. Pharmacological and clinical profile of CP- 601,927: evidence for activity at the nAChR site, 2012 Neuroscience Meeting, New Orleans, LA, Oct 13-17, 2012.
81. Hurst, R. S.; Rollema, H.; Shaffer, C. L.; Coe, J. W.; Bertrand, D. Pharmacological profile of CP-601927 at neuronal nAChRs, 2012 Neuroscience Meeting, New Orleans, LA, Oct 13-17, 2012.
82. Ferry, L. H.; Burchette, R. J. Evaluation of bupropion versus placebo for treatment of nicotine dependence, 147th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 21-26, 1994; pp 199-200.
83. Damaj, M. I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.; Martin, B. R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors Mol. Pharmacol. 2004, 66, 675-682
84. Fryer, J. D.; Lukas, R. J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine J. Pharmacol. Exp. Ther. 1999, 288, 88-92
85. Golden, R. N.; De Vane, C. L.; Laizure, S. C.; Rudorfer, M. V.; Sherer, M. A.; Potter, W. Z. Bupropion in depression. II. The role of metabolites in clinical outcome Arch. Gen. Psychiatry 1988, 45, 145-149
86. Daviss, W. B.; Perel, J. M.; Brent, D. A.; Axelson, D. A.; Rudolph, G. R.; Gilchrist, R.; Nuss, S.; Birmaher, B. Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study Ther. Drug Monit. 2006, 28, 190-198
87. Harvey, S. C.; Maddox, F. N.; Luetje, C. W. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits J. Neurochem. 1996, 67, 1953-1959
88. Crooks, P. A.; Ravard, A.; Wilkins, L. H.; Teng, L.-H.; Buxton, S. T.; Dwoskin, L. P. Inhibition of nicotine-evoked [3H]dopamine release by pyridino N-substituted nicotine analogues: a new class of nicotinic antagonist Drug Dev. Res. 1995, 36, 91-102
89. Andreasen, J. T.; Olsen, G. M.; Wiborg, O.; Redrobe, J. P. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests J. Psychopharmacol. 2009, 23, 797-804
90. Palma, E.; Bertrand, S.; Binzoni, T.; Bertrand, D. Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine J. Physiol. 1996, 491, 151-161
91. Puchacz, E.; Buisson, B.; Bertrand, D.; Lukas, R. J. Functional expression of nicotinic acetylcholine receptors containing rat alpha 7 subunits in human SH-SY5Y neuroblastoma cells FEBS Lett. 1994, 354, 155-159
92. Kaiser, S.; Wonnacott, S. alpha-Bungarotoxin-sensitive nicotinic receptors indirectly modulate [3H]dopamine release in rat striatal slices via glutamate release Mol. Pharmacol. 2000, 58, 312-318
93. Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential ChemMedChem. 2007, 2, 746-767
94. Scharfenberg, G.; Benndorf, S.; Kempe, G. [Cytisine (Tabex) as a pharmaceutical aid in stopping smoking] Dtsch. Gesundheitsw. 1971, 26, 463-465
95. Mineur, Y. S.; Eibl, C.; Young, G.; Kochevar, C.; Papke, R. L.; Gundisch, D.; Picciotto, M. R. Cytisine-based nicotinic partial agonists as novel antidepressant compounds J. Pharmacol. Exp. Ther. 2009, 329, 377-386
96. Mineur, Y. S.; Somenzi, O.; Picciotto, M. R. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice Neuropharmacology 2007, 52, 1256-1262
97. Coe, J. W.; Vetelino, M. G.; Bashore, C. G.; Wirtz, M. C.; Brooks, P. R.; Arnold, E. P.; Lebel, L. A.; Fox, C. B.; Sands, S. B.; Davis, T. I.; Schulz, D. W.; Rollema, H.; Tingley, F. D., 3rd; O'Neill, B. T. In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine Bioorg. Med. Chem. Lett. 2005, 15, 2974-2979
98. Etter, J. F. Cytisine for smoking cessation: a literature review and a meta-analysis Arch. Int. Med. 2006, 166, 1553-1559
99. Reavill, C.; Walther, B.; Stolerman, I. P.; Testa, B. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline Neuropharmacology 1990, 29, 619-624
100. Barlow, R. B.; McLeod, L. J. Some studies on cytisine and its methylated derivatives Br. J. Pharmacol. 1969, 35, 161-174
101. Rollema, H.; Shrikhande, A.; Ward, K. M.; Tingley, F. D., 3rd; Coe, J. W.; O'Neill, B. T.; Tseng, E.; Wang, E. Q.; Mather, R. J.; Hurst, R. S.; Williams, K. E.; de Vries, M.; Cremers, T.; Bertrand, S.; Bertrand, D. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence Br. J. Pharmacol. 2010, 160, 334-345
102. Chellappan, S. K.; Xiao, Y.; Tueckmantel, W.; Kellar, K. J.; Kozikowski, A. P. Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity J. Med. Chem. 2006, 49, 2673-2676
103. Boido, C. C.; Tasso, B.; Boido, V.; Sparatore, F. Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities Farmaco 2003, 58, 265-277
104. Nicolotti, O.; Canu Boido, C.; Sparatore, F.; Carotti, A. Cytisine derivatives as high affinity nAChR ligands: synthesis and comparative molecular field analysis Farmaco 2002, 57, 469-478
105. Coe, J. W.; Brooks, P. R.; Vetelino, M. G.; Wirtz, M. C.; Arnold, E. P.; Huang, J.; Sands, S. B.; Davis, T. I.; Lebel, L. A.; Fox, C. B.; Shrikhande, A.; Heym, J. H.; Schaeffer, E.; Rollema, H.; Lu, Y.; Mansbach, R. S.; Chambers, L. K.; Rovetti, C. C.; Schulz, D. W.; Tingley, F. D., 3rd; O'Neill, B. T. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation J. Med. Chem. 2005, 48, 3474-3477
106. Campion, S. N.; Hurtt, M. E.; Chatman, L. A.; Cappon, G. D. Toxicity study in juvenile rats with the alpha(4) beta(2) nicotinic acetylcholine receptor partial agonist CP-601,927 Birth Defects Res., Part B 2011, 323-332
107. Chatterjee, S.; Steensland, P.; Simms, J. A.; Holgate, J.; Coe, J. W.; Hurst, R. S.; Shaffer, C. L.; Lowe, J.; Rollema, H.; Bartlett, S. E. Partial agonists of the alpha3beta4∗ neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats Neuropsychopharmacology 2011, 36, 603-615
108. A study of the efficacy and safety of CP-601,927 augmentation of antidepressant therapy in major depression. ClinicalTrials.gov, December 29, 2011; http://clinicaltrials.gov/ct2/show/NCT01098240.
109. Mihalak, K. B.; Carroll, F. I.; Luetje, C. W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors Mol. Pharmacol. 2006, 70, 801-805
110. Rollema, H.; Chambers, L. K.; Coe, J. W.; Glowa, J.; Hurst, R. S.; Lebel, L. A.; Lu, Y.; Mansbach, R. S.; Mather, R. J.; Rovetti, C. C.; Sands, S. B.; Schaeffer, E.; Schulz, D. W.; Tingley, F. D., 3rd; Williams, K. E. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology 2007, 52, 985-994
111. Lotfipour, S.; Mandelkern, M.; Alvarez-Estrada, M.; Brody, A. L. A single administration of low-dose varenicline saturates alpha4beta2∗ nicotinic acetylcholine receptors in the human brain Neuropsychopharmacology 2012, 37, 1738-1748
112. Rollema, H.; Guanowsky, V.; Mineur, Y. S.; Shrikhande, A.; Coe, J. W.; Seymour, P. A.; Picciotto, M. R. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect Eur. J. Pharmacol. 2009, 605, 114-116
113. Patterson, F.; Jepson, C.; Strasser, A. A.; Loughead, J.; Perkins, K. A.; Gur, R. C.; Frey, J. M.; Siegel, S.; Lerman, C. Varenicline improves mood and cognition during smoking abstinence Biol. Psychiatry 2009, 65, 144-149
114. Cinciripini, P. M.; Robinson, J. D.; Karam-Hage, M.; Minnix, J. A.; Lam, C.; Versace, F.; Brown, V. L.; Engelmann, J. M.; Wetter, D. W. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal JAMA Psychiatry 2013, 70, 522-533
115. Abreo, M. A.; Lin, N. H.; Garvey, D. S.; Gunn, D. E.; Hettinger, A. M.; Wasicak, J. T.; Pavlik, P. A.; Martin, Y. C.; Donnelly-Roberts, D. L.; Anderson, D. J.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors J. Med. Chem. 1996, 39, 817-825
116. Decker, M. W.; Meyer, M. D.; Sullivan, J. P. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control Expert Opin. Invest. Drugs 2001, 10, 1819-1830
117. Kondo, S.; Marty, A. Synaptic currents at individual connections among stellate cells in rat cerebellar slices J. Physiol. 1998, 509, 221-232
118. Marks, M. J.; Wageman, C. R.; Grady, S. R.; Gopalakrishnan, M.; Briggs, C. A. Selectivity of ABT-089 for alpha4beta2∗ and alpha6beta2∗ nicotinic acetylcholine receptors in brain Biochem. Pharmacol. 2009, 78, 795-802
119. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Piattoni-Kaplan, M.; Campbell, J. E.; McKenna, D. G.; Molinari, E.; Hettinger, A. M.; Garvey, D. S.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha4beta2 nicotinic acetylcholine receptor ligand Neuropharmacology 1996, 35, 725-734
120. Koren, A. O.; Horti, A. G.; Mukhin, A. G.; Gundisch, D.; Kimes, A. S.; Dannals, R. F.; London, E. D. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling J. Med. Chem. 1998, 41, 3690-3698
121. Buckley, M. J.; Surowy, C.; Meyer, M.; Curzon, P. Mechanism of action of A-85380 in an animal model of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28, 723-730
122. Yu, L. F.; Tuckmantel, W.; Eaton, J. B.; Caldarone, B.; Fedolak, A.; Hanania, T.; Brunner, D.; Lukas, R. J.; Kozikowski, A. P. Identification of novel alpha4beta2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity J. Med. Chem. 2012, 55, 812-823
123. Liu, J.; Eaton, J. B.; Caldarone, B.; Lukas, R. J.; Kozikowski, A. P. Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as alpha4beta2-nicotinic acetylcholine receptor-selective partial agonists J. Med. Chem. 2010, 53, 6973-6985
124. Liu, J.; Yu, L. F.; Eaton, J. B.; Caldarone, B.; Cavino, K.; Ruiz, C.; Terry, M.; Fedolak, A.; Wang, D.; Ghavami, A.; Lowe, D. A.; Brunner, D.; Lukas, R. J.; Kozikowski, A. P. Discovery of isoxazole analogues of sazetidine-A as selective alpha4beta2-nicotinic acetylcholine receptor partial agonists for the treatment of depression J. Med. Chem. 2011, 54, 7280-7288
125. Zhang, H.; Tuckmantel, W.; Eaton, J. B.; Yuen, P. W.; Yu, L. F.; Bajjuri, K. M.; Fedolak, A.; Wang, D.; Ghavami, A.; Caldarone, B.; Paterson, N. E.; Lowe, D. A.; Brunner, D.; Lukas, R. J.; Kozikowski, A. P. Chemistry and behavioral studies identify chiral cyclopropanes as selective alpha4beta2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile J. Med. Chem. 2012, 55, 717-724
126. Zwart, R.; Carbone, A. L.; Moroni, M.; Bermudez, I.; Mogg, A. J.; Folly, E. A.; Broad, L. M.; Williams, A. C.; Zhang, D.; Ding, C.; Heinz, B. A.; Sher, E. Sazetidine-A is a potent and selective agonist at native and recombinant alpha4beta2 nicotinic acetylcholine receptors Mol. Pharmacol. 2008, 73, 1838-1843
127. Xiao, Y.; Fan, H.; Musachio, J. L.; Wei, Z. L.; Chellappan, S. K.; Kozikowski, A. P.; Kellar, K. J. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them Mol. Pharmacol. 2006, 70, 1454-1460
128. Kozikowski, A. P.; Eaton, J. B.; Bajjuri, K. M.; Chellappan, S. K.; Chen, Y.; Karadi, S.; He, R.; Caldarone, B.; Manzano, M.; Yuen, P. W.; Lukas, R. J. Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression ChemMedChem. 2009, 4, 1279-1291
129. Turner, J. R.; Castellano, L. M.; Blendy, J. A. Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior J. Pharmacol. Exp. Ther. 2010, 334, 665-672
130. Rezvani, A. H.; Timofeeva, O.; Sexton, H. G.; DeCuir, D.; Xiao, Y.; Gordon, C. J.; Kellar, K. J.; Levin, E. D. Effects of sazetidine-A, a selective alpha4beta2∗ nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats Eur. J. Pharmacol. 2012, 682, 110-117
131. Levin, E. D.; Sexton, H. G.; Gordon, K.; Gordon, C. J.; Xiao, Y.; Kellar, K. J.; Yenugonda, V. M.; Liu, Y.; White, M. P.; Paige, M.; Brown, M. L.; Rezvani, A. H. Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor beta2-/- and alpha7-/- mice Eur. J. Pharmacol. 2013, 718, 167-172
132. Rezvani, A. H.; Cauley, M.; Xiao, Y.; Kellar, K. J.; Levin, E. D. Effects of chronic sazetidine-A, a selective alpha4beta2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats Psychopharmacology 2013, 226, 35-43
133. Cucchiaro, G.; Xiao, Y.; Gonzalez-Sulser, A.; Kellar, K. J. Analgesic effects of sazetidine-A, a new nicotinic cholinergic drug Anesthesiology 2008, 109, 512-519
134. Rezvani, A. H.; Cauley, M.; Sexton, H.; Xiao, Y.; Brown, M. L.; Paige, M. A.; McDowell, B. E.; Kellar, K. J.; Levin, E. D. Sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats Psychopharmacology 2011, 215, 621-630
135. Turner, J. R.; Wilkinson, D. S.; Poole, R. L.; Gould, T. J.; Carlson, G. C.; Blendy, J. A. Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal Neuropsychopharmacology 2013, 38, 2035-2047
136. Hussmann, G. P.; Dedominicis, K. E.; Turner, J. R.; Yasuda, R. P.; Klehm, J.; Forcelli, P. A.; Xiao, Y.; Richardson, J. R.; Sahibzada, N.; Wolfe, B. B.; Lindstrom, J.; Blendy, J. A.; Kellar, K. J. Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain J. Neurochem. 2014, 129, 721-731
137. Johnson, J. E.; Slade, S.; Wells, C.; Petro, A.; Sexton, H.; Rezvani, A. H.; Brown, M. L.; Paige, M. A.; McDowell, B. E.; Xiao, Y.; Kellar, K. J.; Levin, E. D. Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats Psychopharmacology 2012, 222, 269-276
138. Levin, E. D.; Rezvani, A. H.; Xiao, Y.; Slade, S.; Cauley, M.; Wells, C.; Hampton, D.; Petro, A.; Rose, J. E.; Brown, M. L.; Paige, M. A.; McDowell, B. E.; Kellar, K. J. Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats J. Pharmacol. Exp. Ther. 2010, 332, 933-939
139. Rezvani, A. H.; Slade, S.; Wells, C.; Petro, A.; Lumeng, L.; Li, T. K.; Xiao, Y.; Brown, M. L.; Paige, M. A.; McDowell, B. E.; Rose, J. E.; Kellar, K. J.; Levin, E. D. Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats Psychopharmacology 2010, 211, 161-174
140. Hussmann, G. P.; Turner, J. R.; Lomazzo, E.; Venkatesh, R.; Cousins, V.; Xiao, Y.; Yasuda, R. P.; Wolfe, B. B.; Perry, D. C.; Rezvani, A. H.; Levin, E. D.; Blendy, J. A.; Kellar, K. J. Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain J. Pharmacol. Exp. Ther. 2012, 343, 441-450
141. Yu, L. F.; Eaton, J. B.; Fedolak, A.; Zhang, H. K.; Hanania, T.; Brunner, D.; Lukas, R. J.; Kozikowski, A. P. Discovery of highly potent and selective alpha4beta2-nicotinic acetylcholine receptor (nAChR) partial agonists containing an isoxazolylpyridine ether scaffold that demonstrate antidepressant-like activity. Part II J. Med. Chem. 2012, 55, 9998-10009
142. Gatto, G. J.; Bohme, G. A.; Caldwell, W. S.; Letchworth, S. R.; Traina, V. M.; Obinu, M. C.; Laville, M.; Reibaud, M.; Pradier, L.; Dunbar, G.; Bencherif, M. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects CNS Drug Rev. 2004, 10, 147-166
143. Dunbar, G.; Demazieres, A.; Monreal, A.; Cisterni, C.; Metzger, D.; Kuchibhatla, R.; Luthringer, R. Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers J. Clin. Pharmacol. 2006, 46, 715-726
144. Dunbar, G.; Boeijinga, P. H.; Demazieres, A.; Cisterni, C.; Kuchibhatla, R.; Wesnes, K.; Luthringer, R. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers Psychopharmacology 2007, 191, 919-929
145. Dunbar, G. C.; Kuchibhatla, R. V.; Lee, G. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment J. Psychopharmacol. 2011, 25, 1020-1029
146. Frolich, L.; Ashwood, T.; Nilsson, J.; Eckerwall, G. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study J. Alzheimer's Dis. 2011, 24, 363-374
147. Efficacy, safety, & tolerability of AZD3480 patients with mild to moderate dementia of the Alzheimer's Type (AD). TrialsUnited, April 25, 2013; http://www.trialsunited.com/studies/NCT01466088/.
148. Cosford, N. D.; Bleicher, L.; Herbaut, A.; McCallum, J. S.; Vernier, J. M.; Dawson, H.; Whitten, J. P.; Adams, P.; Chavez-Noriega, L.; Correa, L. D.; Crona, J. H.; Mahaffy, L. S.; Menzaghi, F.; Rao, T. S.; Reid, R.; Sacaan, A. I.; Santori, E.; Stauderman, K. A.; Whelan, K.; Lloyd, G. K.; McDonald, I. A. (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors J. Med. Chem. 1996, 39, 3235-3237
149. Rao, T. S.; Adams, P. B.; Correa, L. D.; Santori, E. M.; Sacaan, A. I.; Reid, R. T.; Cosford, N. D. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, altinicline), a novel nicotinic acetylcholine receptor agonist Brain Res. 2008, 1234, 16-24
150. Ferguson, S. M.; Brodkin, J. D.; Lloyd, G. K.; Menzaghi, F. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression Psychopharmacology 2000, 152, 295-303
151. Schneider, J. S.; Pope-Coleman, A.; Van Velson, M.; Menzaghi, F.; Lloyd, G. K. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys Mov. Disord. 1998, 13, 637-642
152. Schneider, J. S.; Tinker, J. P.; Van Velson, M.; Menzaghi, F.; Lloyd, G. K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys J. Pharmacol. Exp. Ther. 1999, 290, 731-739
153. Hajos, M.; Hurst, R. S.; Hoffmann, W. E.; Krause, M.; Wall, T. M.; Higdon, N. R.; Groppi, V. E. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats J. Pharmacol. Exp. Ther. 2005, 312, 1213-1222
154. Tizabi, Y.; Overstreet, D. H.; Rezvani, A. H.; Louis, V. A.; Clark, E., Jr.; Janowsky, D. S.; Kling, M. A. Antidepressant effects of nicotine in an animal model of depression Psychopharmacology 1999, 142, 193-199